Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | ZUMA-11 study overview: axi-cel plus utomilumab in R/R DLBCL

Michael Jain • 8 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Utomilumab
ZUMA-11

Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, gives an overview and update on the ZUMA-11 study of axicabtagene ciloleucel plus utomilumab, an antibody that targets 4-1BB, in patients with refractory diffuse large B-cell lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Michael Jain

2:13
Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T
Michael Jain • 7 Dec 2019
2:25
Does bridging therapy affect lymphoma CAR-T outcomes?
Michael Jain • 8 Dec 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals